Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
(-)-Epigallocatechin gallate
129
CHF
CHF 129.00
In stock
CDX-E0128-M01010 mgCHF 129.00
| Product Details | |
|---|---|
| Synonyms | (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; Epigallocatechin-3-gallate; EGCG; CCRIS 3729; Teavigo; NVP-XAA 723 |
| Product Type | Chemical |
| Properties | |
| Formula |
C22H18O11 |
| MW | 458.37 |
| CAS | 989-51-5 |
| RTECS | KB5200000 |
| Source/Host Chemicals | Plant |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in ethanol (10 mg/ml), DMF (20 mg/ml), DMSO (20 mg/ml) or water (10 mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | WMBWREPUVVBILR-WIYYLYMNSA-N |
| Smiles | OC1=CC([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2OC(C4=CC(O)=C(O)C(O)=C4)=O)=CC(O)=C1O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
(-)-Epigallocatechin gallate (EGCG), an antioxidant and anti-inflammatory polyphenol flavonoid exerts antitumor properties by inhibiting telomerase and DNA methyltransferase activity. EGCG inhibits the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and reduces the invasiveness. EGCG blocks the activation of epidermal growth factor (EGF) receptors and human epidermal growth factor receptor-2 (HER-2). Regulates cancer cell growth, proliferation, transformation, survival, angiogenesis, apoptosis, invasion and metastasis. EGCG increases bone mineral density and reduces bone resorption. EGCG inhibits osteoclastogenesis by inhibiting receptor activator of nuclear factor κB ligand (RANKL) induced nuclear factor κ B (NF-κB) transcriptional activity. EGCG has neuroprotective and anti-aging property and increases myogenic differentiation. EGCG inhibits fatty acid synthase and glutamate dehydrogenase activity. EGCG has preventive cardiovascular and metabolic (obesity, insulin resistance, hypertension and hypercholesterolemia) effects and in vivo, EGCG reduces food intake and body weight, serum levels of insulin, leptin, testosterone and growth hormone.
Product References
(1) Y.J. Surh, et al.; Mutat. Res. 480-481, 243 (2001) (Review) | (2) J. Bain, et al.; Biochem. J. 371, 199 (2003) | (3) N. Khan, et al.; Cancer Res. 66, 2500 (2006) (Review) | (4) W.X. Tian; Curr. Med. Chem. 13, 967 (2006) (Review) | (5) A. Murakami; Forum Nutr. 61, 193 (2009) (Review) | (6) H. Tachibana; Forum Nutr. 61, 156 (2009) (Review) | (7) S.C. Gupta, et al.; Cancer Metastasis Rev. 29, 405 (2010) (Review) | (8) H. Zhou, et al.; Anticancer Agents Med. Chem. 10, 571 (2010) (Review) | (9) F.H. Sarkar, et al.; Cancer Metastasis Rev. 29, 383 (2010) (Review) | (10) S. Sae-tan, et al.; Pharmacol. Res. 64, 146 (2011) (Review) | (11) M.K. Shanmugam, et al.; Nutr. Cancer 63, 161 (2011) (Review) | (12) G. Scapagnini, et al.; Mol. Neurobiol. 44, 192 (2011) (Review) | (13) C.B. Pocernich, et al.; Curr. Alzheimer Res. 8, 452 (2011) (Review) | (14) D. Wu, et al.; Mol. Aspects Med 33, 107 (2012) (Review)